Skip to content
Clinical Trials – home

Krajská zdravotní a.s. - Masarykova nemocnice Ústí nad Labem, o.z.

Verified siteinfo

Czechia Sociální Péče 3316/12a, 401 13 Usti Nad Labem, Czechia

  • 4 trials recruiting
  • Acute myocardial infarction · Crohn's disease · Dermatitis atopic
  • Adults and children

About Specializations

Krajská zdravotní a.s. - Masarykova nemocnice Ústí nad Labem, o.z. in Usti Nad Labem, Czechia specialises in clinical trials of conditions such as Acute myocardial infarction, Crohn's disease, Dermatitis atopic, Cartilage injury, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology, focusing on innovative treatments for digestive disorders. The center's research is particularly concentrated on inflammatory bowel diseases, such as Crohn's Disease, where it explores novel therapeutic approaches to improve patient outcomes.

  • Inflammatory Bowel Disease
  • Endoscopic Innovations
  • Gut Microbiome Research

By integrating cutting-edge research with clinical practice, the center contributes significantly to the understanding and management of complex gastrointestinal conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Sociální Péče 3316/12a401 13 Usti Nad LabemCzechia
Recruiting now
4 trials
Conditions studied
12
Partner status
Verified site

More sites in Usti Nad LabemCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Cartilage injury+2

Recruiting

Study on the Effectiveness of Lenzumestrocel for Treating Knee Cartilage Defects in Patients

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Lenzumestrocel
  • Sponsor:Bioinova a.s.

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Polpharma Biologics S.A.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:PF-06480605
  • Sponsor:F. Hoffmann-La Roche AG

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:BI 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aminocaproic Acid
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.